News

Premier Inc. and Pensiamo Inc. have partnered to launch a new pharmaceutical supply chain solution that was co-developed with UPMC, a world-renowned healthcare provider and insurer.…
Read More...

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power…
Read More...

Roche announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Rozlytrek (entrectinib) for the treatment of adult and paediatric patients with neurotrophic…
Read More...

Voyager Therapeutics announced a restructuring of its gene therapy relationship with Sanofi Genzyme. Under the terms of the agreement, Voyager gains worldwide rights to the VY-HTT01…
Read More...

Lyophilization Services of New England (LSNE) announced the acquisition of a sterile injectables manufacturing facility located in León, Spain. The site, LSNE-León, will complement…
Read More...

Boehringer Ingelheim and OSE Immunotherapeutics SA announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a…
Read More...

Halo Labs Inc. is pleased to announce that it has entered into a non-binding letter of intent (LOI) for the proposed acquisition of Bophelo Bioscience & Wellness (Pty) Ltd…
Read More...

CASI Pharmaceuticals, Inc. a U.S. biopharmaceutical company that is focusing on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China,…
Read More...

The U.S. Food and Drug Administration approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first…
Read More...

Cytovance Biologics announced that it has received a notification letter and an Establishment Inspection Reports (EIRs) from the U.S. Food and Drug Administration (FDA) for its Oklahoma…
Read More...

CymaBay Therapeutics, Inc. announced 12-week topline results from an ongoing 52-week Phase 2b dose-ranging, paired liver biopsy study of seladelpar for the treatment of nonalcoholic…
Read More...

Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. and Mylan N.V. announced the expansion of the companies' current development and commercialization…
Read More...

Amgen and Allergan plc announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI (trastuzumab-anns) for all approved indications of the reference product,…
Read More...

Camargo Pharmaceutical Services announced that it will acquire InSymbiosis, a Canadian drug development partner which improves how biopharma companies outsource R&D. This…
Read More...

Telix Pharmaceuticals Limited, a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or…
Read More...

Terns Pharmaceuticals announced the initiation of a Phase 1 clinical trial of TERN-101, a farnesoid X receptor (FXR) agonist, being developed for the treatment of non-alcoholic…
Read More...

Pfizer Inc. announced positive results from ORAL Shift, a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis (RA). Patients who achieved low…
Read More...

Debiopharm and Ipsen announced renewal of their Decapeptyl agreement, which extends and strengthens their strategic partnership through 2034 for the development, manufacturing and…
Read More...

Novartis announced new data from the MAXIMISE trial evaluating the efficacy and safety of Cosentyx (secukinumab) in the management of axial manifestations of psoriatic arthritis (PsA).…
Read More...

Harbour BioMed (HBM) and Erasmus MC, University Medical Center Rotterdam announced that they have signed a 10-year Memorandum of Understanding (MOU) to enable a broad range of joint…
Read More...